Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT-2766 COVID-19 Vaccine in Japanese Adults
jRCT2051210093Phase 2Completed
- Sponsor
- Medicago Inc.
- Start
- Oct 2021
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of MT-2766 in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Medicago Inc. Started Oct 2021; status: completed.
02
Drugs
MT-2766
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2051210093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051210093.